The stock of UroGen Pharma Ltd. (NASDAQ:URGN) increased by $0.95 on Friday to finish at $22.16, up 4.48 percent. The last five days have seen an average of 573,740 shares of common stock traded. 13 times new highs were reached in the current year, with a gain of $13.29. The average number of shares traded over the last 20 days was 1,341,030, while the average volume over the last 50 days totaled 694,694.
URGN stock appreciated 146.50% since last month. On 07/26/23, the company’s shares reached a one-month low of $8.69. The stock touched a high of $23.93 on 07/28/23, after rallying from a low of $6.87 in 52 weeks. The price of URGN stock has risen by 149.83% or $13.29 this year, reaching a new high 13 times. Still, the stock price is down -7.40% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
URGN stock investors should be aware that UroGen Pharma Ltd. (URGN) stock had its last reported insider trading activity 195 days ago on Jan 31. On Jan 31, Chief Medical Officer Schoenberg Mark sold 1,900 shares at $10.12 each. This transaction resulted in the insider making $19,228. On Jan 31, Smith Jason Drew sold 1,636 shares at a price of US$10.12. After the transaction, the insider now owns 12,600 shares. Chief Medical Officer Schoenberg Mark had earlier sold 258 shares on Oct 31 for $11.85 a share. The transaction was completed for $3,057.
Financial Health
For the three months ended June 29, UroGen Pharma Ltd.’s quick ratio was 3.60, while its current ratio was 3.80, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 87.70% percent. Based on annual data, it had gross profit of $56.7 million and revenue of $64.36 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. URGN’s return on assets (ROA) during the last 12 months has been -83.90%. There was a -997.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 141.60%.
Earnings Surprise
According to UroGen Pharma Ltd.’s quarterly financial report for the quarter that ended June 29, it had $98.3 million in total debt versus $27.17 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $20.7 million, while revenues rose by 19.81% to $17.19 million. It was predicted that UroGen Pharma Ltd.’s quarterly earnings would be -$1.03, but it ended up being -$1.14, beating the consensus by 9.60%. EBITDA was -$22.18 million for the quarter. At the end of UroGen Pharma Ltd.’s most recent quarter ended June 29, its liabilities totaled 229.51 million, while its total debt was $100.42 million. Equity owned by shareholders amounts to $23.45 million.
Technical Picture
Here’s a quick look at UroGen Pharma Ltd.’s (URGN) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 74.08%, suggesting the stock is Overbought, with a 70.18% historical volatility rate.
The stochastic %K and %D were 83.11% and 80.31% respectively, while the average true range (ATR) was 1.92. Based on the 14-day stochastic reading of 88.39%, the RSI (14) reading is 72.09%. On the 9-day MACD Oscillator, the stock is at 0.83, and the 14-day reading is at 2.45.
Analyst Ratings
UroGen Pharma Ltd. (NASDAQ: URGN) was downgraded by Jefferies to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned UroGen Pharma Ltd. (URGN) an Buy rating. URGN is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is URGN’s price target for the next 12 months?
The current consensus forecast for the stock is between $18.00 and $54.00, with a median target price of $42.50. In analyzing these forecasts, the average price target given by analysts for UroGen Pharma Ltd. (URGN) is $39.25.
